Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

The guidance for FY 2025 includes revenue in the range of $2.3 billion to $2.4 billion vs the Street's estimate of $2.1 billion. Let's dive deep into this guidance. Hims & Hers projects 2025 GLP-1 ...

Hims & Hers Health stock dropped 25% after the ... and retain weight loss subscribers in the coming absence of popular GLP-1 compounds.

Between Novo and Lilly, the GLP-1 industry has become an oligopoly with even less threat from compounders like Hims & Hers Health Inc. HIMS after being taken off the drug shortage list.

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced the resolution of the shortage of GLP-1 (semaglutide ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Hims & Hers, the telehealth company catering to millennials, saw its stock drop nearly 5% Thursday morning. The company jumped into the GLP-1 market last May, offering compounded semaglutide ...

That means Hims & Hers Health, which markets compounded versions of the two treatments, can no longer manufacture exact copies of the drugs as they did during the shortage. It also means the gravy ...

Shares of Hims & Hers, an online health and wellness company that sells compounded GLP-1 medications, plummeted 25% on Friday. Hims & Hers CEO Andrew Dudum said in statement posted on X that the ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.